These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 26021818)
1. In vitro effect of ursolic acid on the inhibition of Mycobacterium tuberculosis and its cell wall mycolic acid. Jyoti MA; Zerin T; Kim TH; Hwang TS; Jang WS; Nam KW; Song HY Pulm Pharmacol Ther; 2015 Aug; 33():17-24. PubMed ID: 26021818 [TBL] [Abstract][Full Text] [Related]
2. Antimycobacterial activity of methanolic plant extract of Artemisia capillaris containing ursolic acid and hydroquinone against Mycobacterium tuberculosis. Jyoti MA; Nam KW; Jang WS; Kim YH; Kim SK; Lee BE; Song HY J Infect Chemother; 2016 Apr; 22(4):200-8. PubMed ID: 26867795 [TBL] [Abstract][Full Text] [Related]
3. In Vitro Effect of DFC-2 on Mycolic Acid Biosynthesis in Kim S; Seo H; Mahmud HA; Islam MI; Kim YS; Lyu J; Nam KW; Lee BE; Lee KI; Song HY J Microbiol Biotechnol; 2017 Nov; 27(11):1932-1941. PubMed ID: 28870005 [TBL] [Abstract][Full Text] [Related]
4. In vitro activity of a novel antimycobacterial compound, N-octanesulfonylacetamide, and its effects on lipid and mycolic acid synthesis. Parrish NM; Houston T; Jones PB; Townsend C; Dick JD Antimicrob Agents Chemother; 2001 Apr; 45(4):1143-50. PubMed ID: 11257028 [TBL] [Abstract][Full Text] [Related]
5. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. Alahari A; Trivelli X; Guérardel Y; Dover LG; Besra GS; Sacchettini JC; Reynolds RC; Coxon GD; Kremer L PLoS One; 2007 Dec; 2(12):e1343. PubMed ID: 18094751 [TBL] [Abstract][Full Text] [Related]
6. Exocarpic acid inhibits mycolic acid biosynthesis in Mycobacterium tuberculosis. Koch M; Bugni TS; Sondossi M; Ireland CM; Barrows LR Planta Med; 2010 Oct; 76(15):1678-82. PubMed ID: 20506078 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and Structural Activity Relationship Study of Ursolic Acid Derivatives as Antitubercular Agent. Vishwakarma S; Srivastava SK; Khare NK; Chaubey S; Chaturvedi V; Trivedi P; Khan S; Khan F Med Chem; 2024; 20(6):630-645. PubMed ID: 37946341 [TBL] [Abstract][Full Text] [Related]
8. [Biosynthesis and regulation of mycolic acids in Mycobacterium tuberculosis--a review]. Luo H; Pang L; Xie J Wei Sheng Wu Xue Bao; 2012 Feb; 52(2):146-51. PubMed ID: 22586991 [TBL] [Abstract][Full Text] [Related]
9. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Tahlan K; Wilson R; Kastrinsky DB; Arora K; Nair V; Fischer E; Barnes SW; Walker JR; Alland D; Barry CE; Boshoff HI Antimicrob Agents Chemother; 2012 Apr; 56(4):1797-809. PubMed ID: 22252828 [TBL] [Abstract][Full Text] [Related]
10. Ursolic Acid Activates Intracellular Killing Effect of Macrophages During Mycobacterium tuberculosis Infection. Podder B; Jang WS; Nam KW; Lee BE; Song HY J Microbiol Biotechnol; 2015 May; 25(5):738-44. PubMed ID: 25406534 [TBL] [Abstract][Full Text] [Related]
11. Effects of isoniazid on ultrastructure of Mycobacterium aurum and Mycobacterium tuberculosis and on production of secreted proteins. Bardou F; Quémard A; Dupont MA; Horn C; Marchal G; Daffé M Antimicrob Agents Chemother; 1996 Nov; 40(11):2459-67. PubMed ID: 8913447 [TBL] [Abstract][Full Text] [Related]
12. Characterization of 7-amino-4-methylcoumarin as an effective antitubercular agent: structure-activity relationships. Tandon R; Ponnan P; Aggarwal N; Pathak R; Baghel AS; Gupta G; Arya A; Nath M; Parmar VS; Raj HG; Prasad AK; Bose M J Antimicrob Chemother; 2011 Nov; 66(11):2543-55. PubMed ID: 21917615 [TBL] [Abstract][Full Text] [Related]
13. Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis. Schroeder EK; de Souza N; Santos DS; Blanchard JS; Basso LA Curr Pharm Biotechnol; 2002 Sep; 3(3):197-225. PubMed ID: 12164478 [TBL] [Abstract][Full Text] [Related]
14. Mycolic acids, a promising mycobacterial ligand for targeting of nanoencapsulated drugs in tuberculosis. Lemmer Y; Kalombo L; Pietersen RD; Jones AT; Semete-Makokotlela B; Van Wyngaardt S; Ramalapa B; Stoltz AC; Baker B; Verschoor JA; Swai HS; de Chastellier C J Control Release; 2015 Aug; 211():94-104. PubMed ID: 26055640 [TBL] [Abstract][Full Text] [Related]
16. IQG-607 abrogates the synthesis of mycolic acids and displays intracellular activity against Mycobacterium tuberculosis in infected macrophages. Rodrigues-Junior VS; dos Santos Junior AA; Villela AD; Belardinelli JM; Morbidoni HR; Basso LA; Campos MM; Santos DS Int J Antimicrob Agents; 2014 Jan; 43(1):82-5. PubMed ID: 24139881 [TBL] [Abstract][Full Text] [Related]
17. New approaches to target the mycolic acid biosynthesis pathway for the development of tuberculosis therapeutics. North EJ; Jackson M; Lee RE Curr Pharm Des; 2014; 20(27):4357-78. PubMed ID: 24245756 [TBL] [Abstract][Full Text] [Related]
18. Determination of the primary target for isoniazid in mycobacterial mycolic acid biosynthesis with Mycobacterium aurum A+. Wheeler PR; Anderson PM Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):451-7. PubMed ID: 8809032 [TBL] [Abstract][Full Text] [Related]
19. [The mycolic acids analysis with HPLC technique in drug susceptibility testing of Mycobacterium tuberculosis strains]. Walkiewicz R; Grubek-Jaworska H; Chazan R Pneumonol Alergol Pol; 2006; 74(1):89-94. PubMed ID: 17175985 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological aspects of mycolic acids: an important target against Mycobacterium tuberculosis. de Souza MV; Ferreira Mde L; Pinheiro AC; Saraiva MF; de Almeida MV; Valle MS ScientificWorldJournal; 2008 Jul; 8():720-51. PubMed ID: 18677428 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]